Physician profile
Tamara Lior
NPI 1376503946
$3,738.57
in general payments reported to CMS, 2019-2025
25 companies · $935 in 2025
The $935 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2021: $138 · 2022: $19.90 · 2024: $2,396 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,379 · Travel and Lodging: $897 · Consulting Fee: $54.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,378.80 |
| Travel and Lodging | $896.93 |
| Consulting Fee | $54.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mimedx Group, INC. | $1,287.66 | 2024 | |
| Abbvie INC. | $362.94 | 2024-2025 | |
| Pfizer INC. | $226.74 | 2024-2025 | |
| Almirall LLC | $223.47 | 2019-2025 | Klisyri, Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $154.13 | 2019-2024 | Cabtreo |
| Biofrontera INC. | $142.62 | 2024-2025 | Xepi, Bf-Rhodoled, Ameluz |
| Galderma Laboratories, L.P. | $130.17 | 2024-2025 | Aklief |
| Janssen Scientific Affairs, LLC | $117.67 | 2021 | |
| Leo Pharma INC. | $108.20 | 2025 | Anzupgo |
| E.R. Squibb & Sons, L.L.C. | $105.78 | 2024 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $102.89 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $101.73 | 2024 | Nuzyra |
| Solta Medical, A Division of Bausch Health US, LLC | $99.51 | 2025 | |
| Janssen Biotech, INC. | $92.84 | 2019-2025 | Tremfya |
| Kerecis Limited | $92.59 | 2022-2025 | Kerecis Surgiclose, Kerecis Graftguide |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $85.61 | 2024-2025 | Bimzelx |
| Convatec INC. | $67.52 | 2025 | |
| Novartis Pharmaceuticals Corporation | $59.02 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $40.26 | 2025 | Libtayo |
| Genzyme Corporation | $39.69 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.89 | 2024 | Spevigo |
| Amgen INC. | $20.80 | 2021 | |
| Arcutis Biotherapeutics, INC. | $17.46 | 2024 | Zoryve |
| Lilly USA, LLC | $16.80 | 2024 | Olumiant |
| Lnhc, INC | $16.58 | 2025 | Zelsuvmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Lior listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.